Epidemiology of HIV cardiac disease

Progress in Cardiovascular Diseases

Volumn 45, Issue 4, 2003, Pages 319-326

  Cotter, Bruno R ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENDOCARDITIS; ENDOTHELIUM LESION; HEART ARRHYTHMIA; HEART DILATATION; HEART DISEASE; HEART INFARCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; LYMPHOMA; MYOCARDITIS; PERICARDIAL EFFUSION; PREVALENCE; REVIEW;

EID: 0037222756     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2003.5     Document Type: Review

References (84)

1. DeCastro S, Migliau G, Silvestri A, et al: Heart involvement in AIDS: A prospective study during various stages of the disease. Eur Heart J 13:1452-1459, 1992
2. Milei J, Grana D, Fernandez Alonso G, et al: Cardiac involvement in acquired immunodeficiency syndrome - a review to push action. Clin Cardiol 21:465-472, 1998
3. Mocroft A, Katlama C, Johnson AM, et al: AIDS across Europe, 1994-98: The EuroSIDA study. Lancet 356:291-296, 2000
4. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860, 1998
5. Barbaro G, Di Lorenzo G, Grisorio B, et al: Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinical-pathological study. AIDS Res Hum Retroviruses 14:1071-1077, 1998
6. Yunis NA, Stone VE: Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 18:145-154, 1998
7. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, et al: Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 160:602-608, 2000
8. Paton P, Tabib A, Loire R, et al: Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144:225-231, 1993
9. Tabib A, Leroux C, Mornex JF, et al: Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 11:41-46, 2000
10. Cohen IS, Anderson DW, Virmani R, et al: Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 315:628-630, 1986
11. Levy WS, Simon GL, Rios JC, et al: Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 63:86-89, 1989
12. Herskowitz A, Vlahov D, Willoughby S, et al: Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 71:955-958, 1993
13. De Castro S, d'Amati G, Gallo P, et al: Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 24:1018-1024, 1994
14. Barbaro G, Di Lorenzo G, Grisorio B, et al: Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N Engl J Med 339:1093-1099, 1998
15. Lipshultz SE: Dilated cardiomyopathy in HIV-infected patients. N Engl J Med 339:1153-1155, 1998
16. Lipshultz SE, Easley KA, Orav EJ, et al: Left ventricular structure and function in children infected with human immunodeficiency virus: The prospective P2C2 HIV multicenter study. Circulation 97:1246-1256, 1998
17. Anderson DW, Virmani R, Reilly JM, et al: Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol 11:792-799, 1988
18. d'Amati G, di Gioia CR, Gallo P: Pathological findings of HIV-associated cardiovascular disease. Ann N Y Acad Sci 946:23-45, 2001
19. Baroldi G, Corallo S, Moroni M, et al: Focal lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): A correlative morphologic and clinical study in 26 consecutive fatal cases. J Am Coll Cardiol 12:463-469, 1988
20. Herskowitz A, Wu TC, Willoughby SB, et al: Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 24:1025-1032, 1994
21. Barbaro G, Di Lorenzo G, Soldini M, et al: Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 100:933-939, 1999
22. Kasten-Sportes C, Weinstein C: Molecular mechanisms of HIV cardiovascular disease, in Lipshultz SE, ed. Cardiology in AIDS. New York: Chapman & Hall, 1998, pp 265-282
23. Currie PF, Goldman JH, Caforio AL, et al: Cardiac autoimmunity in HIV related heart muscle disease. Heart 79:599-604, 1998
24. Francis C: Cardiac Involvement in AIDS: Current Problems in Cardiology. St. Louis, MO: Mosby, 1990
25. Ellner JJ, Rosenthal MS, Lerner PI, et al: Infective endocarditis caused by slow-growing, fastidious, gram-negative bacteria. Medicine (Baltimore) 58:145-158, 1979
26. Guarda LA, Luna MA, Smith JL Jr, et al: Acquired immune deficiency syndrome: Postmortem findings. Am J Clin Pathol 81:549-557, 1984
27. Henochowicz S, Mustafa M, Lawrinson WE, et al: Cardiac aspergillosis in acquired immune deficiency syndrome. Am J Cardiol 55:1239-1240, 1985
28. Kaul S, Fishbein MC, Siegel RJ: Cardiac manifestations of acquired immune deficiency syndrome: A 1991 update. Am Heart J 122:535-544, 1991
29. Roldan EO, Moskowitz L, Hensley GT: Pathology of the heart in acquired immunodeficiency syndrome. Arch Pathol Lab Med 111:943-946, 1987
30. Cammarosano C, Lewis W: Cardiac lesions in acquired immune deficiency syndrome (AIDS). J Am Coll Cardiol 5:703-706, 1985
31. Fink L, Reichek N, Sutton MG: Cardiac abnormalities in acquired immune deficiency syndrome. Am J Cardiol 54:1161-1163, 1984
32. Kinney EL, Brafman D, Wright RJ 2nd: Echocardiographic findings in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). Cathet Cardiovasc Diagn 16:182-185, 1989
33. Chen Y, Brennessel D, Walters J, et al: Human immunodeficiency virus-associated pericardial effusion: Report of 40 cases and review of the literature. Am Heart J 137:516-521, 1999
34. Silva-Cardoso J, Moura B, Martins L, et al: Pericardial involvement in human immunodeficiency virus infection. Chest 115:418-422, 1999
35. Woods GL, Goldsmith JC: Fatal pericarditis due to Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome. Chest 95:1355-1357, 1989
36. Freedberg RS, Gindea AJ, Dieterich DT, et al: Herpes simplex pericarditis in AIDS. N Y State J Med 87:304-306, 1987
37. Holtz HA, Lavery DP, Kapila R: Actinomycetales infection in the acquired immunodeficiency syndrome. Ann Intern Med 102:203-205, 1985
38. Zuger A, Louie E, Holzman RS, et al: Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med 104:234-240, 1986
39. Estok L, Wallach F: Cardiac tamponade in a patient with AIDS: A review of pericardial disease in patients with HIV infection. Mt Sinai J Med 65:33-39, 1998
40. Himelman RB, Chung WS, Chernoff DN, et al: Cardiac manifestations of human immunodeficiency virus infection: A two-dimensional echocardiographic study. J Am Coll Cardiol 13:1030-1036, 1989
41. Wahr DW, Wang YS, Schiller NB: Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population. J Am Coll Cardiol 1:863-868, 1983
42. Pellicelli AM, Palmieri F, D'Ambrosio C, et al: Role of human immunodeficiency virus in primary pulmonary hypertension - case reports. Angiology 49:1005-1011, 1998
43. Pellicelli AM, Barbaro G, Palmieri F, et al: Primary pulmonary hypertension in HIV patients: A systematic review. Angiology 52:31-41, 2001
44. Himelman RB, Dohrmann M, Goodman P, et al: Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 64:1396-1399, 1989
45. Neild PJ, Amadi A, Ponikowski P, et al: Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. Int J Cardiol 74:133-137, 2000
46. Levine AM: Lymphoma complicating immunodeficiency disorders. Ann Oncol 5:29-35, 1994 (suppl 2)
47. Balasubramanyam A, Waxman M, Kazal HL, et al: Malignant lymphoma of the heart in acquired immune deficiency syndrome. Chest 90:243-246, 1986
48. Holladay AO, Siegel RJ, Schwartz DA: Cardiac malignant lymphoma in acquired immune deficiency syndrome. Cancer 70:2203-2207, 1992
49. McDonnell PJ, Mann RB, Bulkley BH: Involvement of the heart by malignant lymphoma: A clinicopathologic study. Cancer 49:944-951, 1982
50. Steigman CK, Anderson DW, Macher AM, et al: Fatal cardiac tamponade in acquired immunodeficiency syndrome with epicardial Kaposi's sarcoma. Am Heart J 116:1105-1107, 1988
51. Stotka JL, Good CB, Downer WR, et al: Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome. Chest 95:1359-1361, 1989
52. Passalaris JD, Sepkowitz KA, Glesby MJ: Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 31:787-797, 2000
53. Carr A, Samaras K, Burton S, et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58, 1998
54. Chi D, Henry J, Kelley J, et al: The effects of HIV infection on endothelial function. Endothelium 7:223-242, 2000
55. Hadigan C, Meigs JB, Rabe J, et al: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 86:939-943, 2001
56. Lumpkin M: FDA public health advisory: Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Washington, DC: US Government Printing Office, 1997
57. Behrens G, Dejam A, Schmidt H, et al: Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13:F63-F70, 1999
58. Walli R, Herfort O, Michl GM, et al: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12:F167-F173, 1998
59. Segerer S, Bogner JR, Walli R, et al: Hyperlipidemia under treatment with proteinase inhibitors. Infection 27:77-81, 1999
60. Sullivan AK, Nelson MR: Marked hyperlipidaemia on ritonavir therapy. AIDS 11:938-939, 1997
61. Churchill DR, Pym AS, Babiker AG, et al: Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol 46:518-519, 1998
62. Gordon DJ, Probstfield JL, Garrison RJ, et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989
63. Periard D, Telenti A, Sudre P, et al: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100:700-705, 1999
64. Assmann G, Schulte H, von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179-1184, 1996
65. Carr A, Samaras K, Chisholm DJ, et al: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-1883, 1998
66. Wanke CA: Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 13:1287-1293, 1999
67. Mallal SA, John M, Moore CB, et al: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309-1316, 2000
68. Brinkman K, Smeitink JA, Romijn JA, et al: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112-1115, 1999
69. Caron M, Auclair M, Vigouroux C, et al: The HIV-protease inhibitor indinavir impairs adipocyte differentiation and induces insulin resistance by probably altering ADD1/SREBP-1 maturation. Antiviral Ther 5:4, 2000 (abstr 3, suppl 5)
70. Hadigan C, Meigs JB, Corcoran C, et al: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130-139, 2001
71. Glasser SP, Selwyn AP, Ganz P: Atherosclerosis: Risk factors and the vascular endothelium. Am Heart J 131:379-384, 1996
72. Celermajer DS, Sorensen KE, Bull C, et al: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24:1468-1474, 1994
73. Suwaidi JA, Hamasaki S, Higano ST, et al: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954, 2000
74. Stein JH, Klein MA, Bellehumeur JL, et al: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262, 2001
75. Zhong DS, Lu XH, Conklin BS, et al: HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22:1560-1566, 2002
76. Barbaro G, Barbarini G, Pellicelli AM: HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 344:1799-1800, 2001
77. Flynn TE, Bricker LA: Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 131:548, 1999
78. Friedl AC, Attenhofer Jost CH, Schalcher C, et al: Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 14:2790-2792, 2000
79. Karmochkine M, Raguin G: Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 12:2499, 1998
80. Klein D, Hurley L, Sidney S: Do protease inhibitors increase the risk for coronary heart disease among HIV-positive patients? Additional follow-up. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January 30-February 2, 2000, p 81 (abstr 33)
81. Rickerts V, Brodt H, Staszewski S, et al: Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. Eur J Med Res 5:329-333, 2000
82. Niaura R, Shadel WG, Morrow K, et al: Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin Infect Dis 31:808-812, 2000
83. Mattana J, Siegal FP, Sankaran RT, et al: Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 317:232-237, 1999
84. Margolin A, Avants SK, Setaro JF, et al: Cocaine, HIV, and their cardiovascular effects: Is there a role for ACE-inhibitor therapy? Drug Alcohol Depend 61:35-45, 2000